Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.66 EUR | +2.74% | +3.72% | +33.91% |
05-07 | Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost | RE |
05-07 | Japan's Nikkei climbs on Fed rate-cut outlook, tech boost | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 62.02 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.91% | 66.54B | - | ||
+31.06% | 682B | C+ | ||
+30.35% | 586B | B | ||
-3.42% | 364B | C+ | ||
+18.02% | 327B | B- | ||
+4.27% | 285B | C+ | ||
+15.53% | 240B | B+ | ||
+10.16% | 209B | B- | ||
-8.14% | 203B | A+ | ||
+8.12% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4568 Stock
- D4S Stock
- Ratings Daiichi Sankyo Co., Ltd.